Oncothyreon forges $20M equity deal; HHS Secretary empathizes with drug developers;

@FierceBiotech: Sanofi's rumored buyout plans inspire guessing game. Article  | Follow @FierceBiotech

@JohnCFierce: Bad year for Xenoport, which had to slash its staff by 50 percent after the FDA rejected its drug for RLS. Now the same drug flunks migraine study. Follow @JohnCFierce

> Now that Merck KGaA has a green light to resume clinical trials on its cancer vaccine, Oncothyreon has announced that an investor has agreed to buy up to $20 million worth of its shares at an agreed discount. Report

> HHS Secretary Kathleen Sebelius journeyed to Kansas this week to hear more about all the challenges faced by drug developers. Story

> The FDA has expanded its approval for Shire's ADHD drug Daytrana to include adolescents aged 13 to 17. Story

> Molecular Templates has struck a research and discovery deal with Imclone, a unit of Eli Lilly. The company will ID toxin bodies against an undisclosed cancer target. Report

> Cipher Pharmaceuticals announced that it reached a cumulative sales milestone for Lipofen, triggering a $1 million milestone payment from Kowa Pharmaceuticals America. Cipher release

And Finally... Ultrasound scanners often rely on tiny, gas-filled bubbles to sharpen the images they capture. But certain ultrasound signals are known to burst those bubbles. And now a cross-disciplinary team of researchers at Leeds University will explore whether the phenomenon can be put to use as a new drug delivery tool. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.